The anti-cancer properties of HDAC inhibitors.

Histone deacetylase (HDAC) inhibition is a process in which enzymes that normally remove acetyl groups from histones are blocked. Histones are proteins that form part of the structure of chromosomes, and their acetylation or deacetylation affects several cellular processes, including gene expression, DNA repair, and cell differentiation. Inhibition of HDACs increases the level of histone acetylation, which has been shown to have a wide range of effects on gene expression and cellular function. HDAC inhibitors are being studied as potential treatments for a variety of diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

HDAC inhibition can counteract the abnormal acetylation status of proteins found in cancer cells and can reactivate the expression of tumor suppressors {ref}










"in SCLC cells, the gene responsible for making NKG2DL is hidden behind tightly coiled DNA, making it impossible for the cellular machinery that translates this gene into a protein to access it. When the researchers dosed animal models of SCLC with drugs called histone deacetylase (HDAC) inhibitors, which loosen DNA coils, the SCLC cells began expressing NKG2DL on their surfaces, translating into significantly smaller tumors that had more activated immune cells."


Phenylbutyrate is a prodrug that is metabolized to phenylacetate, which is the active molecule that combines with glutamine (an amino acid with two nitrogen molecules) to form phenylacetylglutamine which is rapidly excreted by the kidneys and does not require metabolism via the urea cycle. Phenylbutyrate thus provides an “ammonia sink”, an alternative pathway for excretion of excess nitrogen and ammonia Ref
  • Peptides {review}
    • Antineoplastons A10 and AS2-1
  • Cyproheptadine, an anti-histaminic, synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor. {study}
cyproheptadine demonstrated activity in in vitro and in vivo models of MCL with a mechanism of action resembling a classic HDACI

Natural Bioactive Compounds Targeting Histone Deacetylases in Human Cancers: Recent Updates

Examples of dietary compounds that regulate histone acetylation.

Books

  • Fighting Cancer Through HDAC and MAPK Inhibitors by Anna Purna Edara
  • Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy by Ganai, Shabir Ahmad

Illustrations

https://www.mdpi.com/2073-4409/8/8/930




No comments:

Post a Comment